A ruling by a Missouri judge suggests thousands of talcum powder ovarian cancer lawsuits filed in that state were correctly filed due to links between the manufacturer and a Missouri-based distribution company.…
A federal judge has rejected claims by C.R. Bard that it is protected from IVC filter lawsuits by federal law.…
Talcum powder cancer lawsuit filings in New Jersey federal court have nearly tripled over the last month, due mainly to a Supreme Court ruling which changed the requirements for product liability lawsuits to be filed at the state level.…
The Supreme Court has refused to overturn previous decisions allowing a class action lawsuit against Conagra over its decision to call Wesson cooking oil “100% natural” despite the use of genetically modified crops.…
The FDA has again delayed a long-anticipated rule that would make generic drug manufacturers responsible for updating their labels to warn the medical community and patients about potentially deadly side effects that may not have been known when the drug was available as a brand name.…
Johnson & Johnson is trying to have numerous talcum powder ovarian cancer lawsuits filed by out-of-state residents in St. Louis Circuit Court dismissed following a Supreme Court ruling on where personal injury claims can be filed.…
A Supreme Court ruling may have far-reaching impacts on consolidation of product liability lawsuits, and has already resulted in a mistrial in a St. Louis talcum powder cancer trial.…
The Supreme court has overturned a $2,7 million punitive award against Goodyear, over the company’s discovery misconduct in a tire blowout lawsuit, saying that such penalties must only compensate the other party for additional legal fees incurred by the discovery activities that were conducted in bad faith.…
California’s highest court is weighing whether brand name drug manufacturers can be held liable for failure to warn claims involving generic versions, which must exactly clone the brand name warning label under federal law.…
A federal judge has ruled that plaintiffs can continue to pursue off-label marketing claims against generic testosterone drug manufacturers, even though failure to warn claims are preempted.…
